Literature DB >> 9848286

Strategies to improve insurance coverage for infertility services.

N Gleicher.   

Abstract

Various studies repeatedly have demonstrated that in the United States, only a minority of couples with infertility receive medical treatment and even fewer receive such treatment from specialists. Primarily couples of higher socioeconomic status receive such treatment. It is therefore obvious that a lack of insurance coverage greatly contributes to this country's disproportionately low utilization of fertility services compared with other developed nations. Such low utilization raises significant ethical and economic issues. For example, if the treatment of infertility is to be perceived as the treatment of a disease stage (a notion widely supported in our professional community), then how can we defend the fact that services are principally available only to the affluent? Moreover, by having access to only a fraction of the potential national market for infertility services, the national overhead for these services is distributed over only a fraction of potential buyers, greatly increasing unit costs. In short, obtaining a larger market for our services through better insurance coverage would solve ethical quandaries and, at the same time, reduce fertility costs on a unit level. How, then, can such improved insurance coverage be achieved? A number of possible strategies come to mind.

Entities:  

Mesh:

Year:  1998        PMID: 9848286     DOI: 10.1016/s0015-0282(98)00383-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  A small field for fertile science: the low visibility of reproductive science in high impact journals.

Authors:  Francesca E Duncan; Benjamin Derman; Teresa K Woodruff
Journal:  J Assist Reprod Genet       Date:  2014-03-21       Impact factor: 3.412

2.  The "graying" of infertility services: an impending revolution nobody is ready for.

Authors:  Norbert Gleicher; Vitaly A Kushnir; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2014-07-09       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.